Trends in Mitochondrial Therapeutics for Neurological Disease

Current Medicinal Chemistry

Volumn 22, Issue 20, 2015, Pages 2458-2467

  Leitão Rocha, Ana ^a   Guedes Dias, Pedro ^a   Pinho, Brígida R ^a   Oliveira, Jorge M A ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

Experimental therapeutics; gene therapy; mitochondria; mitochondrial disease; mitochondrial dynamics; neurodegeneration; neurological disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; AMINO ACID TRANSFER RNA LIGASE; ANTIOXIDANT; BEZAFIBRATE; CATION; CELL NUCLEUS DNA; ENTINOSTAT; GRAMICIDIN S; HYDRAZONE DERIVATIVE; HYDRAZONE M1; MITOCHONDRIAL DNA; NUCLEASE; PARKIN; PEPTIDE; PEPTIDE NUCLEIC ACID; PIOGLITAZONE; RESTRICTION ENDONUCLEASE; ROSIGLITAZONE; ROTENONE; TRANSFER RNA; TUBACIN; UBIQUINONE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; BIOGENESIS; CELL MOTION; CHROMOSOME; CLINICAL TRIAL (TOPIC); DISEASE TRANSMISSION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG DELIVERY SYSTEM; EXERCISE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; MITOCHONDRIAL DYNAMICS; MITOCHONDRIAL GENE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MITOPHAGY; NERVE CELL LESION; NEUROLOGIC DISEASE; NONHUMAN; POLAR BODY; SPINDLE CELL; TREND STUDY; WILD TYPE; ANIMAL; DRUG EFFECTS; GENETICS; METABOLISM; NERVOUS SYSTEM DISEASES; PATHOLOGY;

ANIMALS; DNA, MITOCHONDRIAL; HUMANS; MITOCHONDRIA; NERVOUS SYSTEM DISEASES;

EID: 84938631143     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867322666150209160317     Document Type: Article

References (145)

1. Kann O, Kovacs R. Mitochondria and neuronal activity. Am J Physiol Cell Physiol 2007; 292:C641-57
2. Koopman WJ, Distelmaier F, Smeitink JA, Willems PH. OXPHOS mutations and neurodegeneration. EMBO J 2013; 32:9-29
3. Tuppen HA, Blakely EL, Turnbull DM, Taylor RW. Mitochondrial DNA mutations and human disease. Biochim Biophys Acta 2010; 1797:113-28
4. DiMauro S, Schon EA, Carelli V, Hirano M. The clinical maze of mitochondrial neurology. Nat Rev Neurol 2013; 9:429-44
5. McFarland R, Taylor RW, Turnbull DM. A neurological perspective on mitochondrial disease. Lancet Neurol 2010; 9:829-40
6. Schon EA, Przedborski S. Mitochondria: the next (neurode) generation. Neuron 2011; 70:1033-53
7. Oliveira JM. Mitochondrial bioenergetics and dynamics in Huntington's disease: tripartite synapses and selective striatal degeneration. J Bioenerg Biomembr 2010; 42:227-34
8. Oliveira JM, Goncalves J. In situ mitochondrial Ca2+ buffering differences of intact neurons and astrocytes from cortex and striatum. J Biol Chem 2009; 284:5010-20
9. Pinto M, Pickrell AM, Moraes CT. Regional susceptibilities to mitochondrial dysfunctions in the CNS. Biol Chem 2012; 393:275-81
10. Trounce IA, Pinkert CA. Cybrid models of mtDNA disease and transmission, from cells to mice. Curr Top Dev Biol 2007; 77:157-83
11. Barrientos A. Yeast models of human mitochondrial diseases. IUBMB Life 2003; 55:83-95
12. Abramov AY, Smulders-Srinivasan TK, Kirby DM, Acin-Perez R, Enriquez JA, Lightowlers RN, et al. Mechanism of neurodegeneration of neurons with mitochondrial DNA mutations. Brain 2010; 133:797-807
13. Oliveira JM. Techniques to investigate neuronal mitochondrial function and its pharmacological modulation. Curr Drug Targets 2011; 12:762-73
14. Farrar GJ, Chadderton N, Kenna PF, Millington-Ward S. Mitochondrial disorders: aetiologies, models systems, and candidate therapies. Trends Genet 2013; 29:488-97
15. Tyynismaa H, Suomalainen A. Mouse models of mitochondrial DNA defects and their relevance for human disease. EMBO Rep 2009; 10:137-43
16. Steele SL, Prykhozhij SV, Berman JN. Zebrafish as a model system for mitochondrial biology and diseases: a review. Transl Res 2013
17. Pinho BR, Santos MM, Fonseca-Silva A, Valentao P, Andrade PB, Oliveira JM. How mitochondrial dysfunction affects zebrafish development and cardiovascular function: an in vivo model for testing mitochondria-targeted drugs. Br J Pharmacol 2013; 169:1072-90
18. Sanchez-Martinez A, Luo N, Clemente P, Adan C, Hernandez-Sierra R, Ochoa P, et al. Modeling human mitochondrial diseases in flies. Biochim Biophys Acta 2006; 1757:1190-8
19. Ventura N, Rea SL. Caenorhabditis elegans mitochondrial mutants as an investigative tool to study human neurodegenerative diseases associated with mitochondrial dysfunction. Biotechnol J 2007; 2:584-95
20. Pfeffer G, Horvath R, Klopstock T, Mootha VK, Suomalainen A, Koene S, et al. New treatments for mitochondrial disease-no time to drop our standards. Nat Rev Neurol 2013; 9:474-81
21. Vento JM, Pappa B. Genetic counseling in mitochondrial disease. Neurotherapeutics 2013; 10:243-50
22. Mitalipov S, Amato P, Parry S, Falk MJ. Limitations of preimplantation genetic diagnosis for mitochondrial DNA diseases. Cell Rep 2014; 7:935-7
23. Craven L, Elson JL, Irving L, Tuppen HA, Lister LM, Greggains GD, et al. Mitochondrial DNA disease: new options for prevention. Hum Mol Genet 2011; 20:R168-74
24. Amato P, Tachibana M, Sparman M, Mitalipov S. Three-parent in vitro fertilization: gene replacement for the prevention of inherited mitochondrial diseases. Fertil Steril 2014; 101:31-5
25. Sato A, Kono T, Nakada K, Ishikawa K, Inoue S, Yonekawa H, et al. Gene therapy for progeny of mito-mice carrying pathogenic mtDNA by nuclear transplantation. Proc Natl Acad Sci U S A 2005; 102:16765-70
26. Craven L, Tuppen HA, Greggains GD, Harbottle SJ, Murphy JL, Cree LM, et al. Pronuclear transfer in human embryos to prevent transmission of mitochondrial DNA disease. Nature 2010; 465:82-5
27. Tachibana M, Sparman M, Sritanaudomchai H, Ma H, Clepper L, Woodward J, et al. Mitochondrial gene replacement in primate offspring and embryonic stem cells. Nature 2009; 461:367-72
28. Tachibana M, Amato P, Sparman M, Woodward J, Sanchis DM, Ma H, et al. Towards germline gene therapy of inherited mitochondrial diseases. Nature 2013; 493:627-31
29. Paull D, Emmanuele V, Weiss KA, Treff N, Stewart L, Hua H, et al. Nuclear genome transfer in human oocytes eliminates mitochondrial DNA variants. Nature 2013; 493:632-7
30. Chinnery PF, Craven L, Mitalipov S, Stewart JB, Herbert M, Turnbull DM. The challenges of mitochondrial replacement. PLoS Genet 2014; 10:e1004315
31. Chinnery PF, Hudson G. Mitochondrial genetics. Br Med Bull 2013; 106:135-59
32. Wang T, Sha H, Ji D, Zhang HL, Chen D, Cao Y, et al. Polar body genome transfer for preventing the transmission of inherited mitochondrial diseases. Cell 2014; 157:1591-604
33. Wolf DP, Mitalipov S. Mitochondrial replacement therapies can circumvent mtDNA-based disease transmission. Cell Metab 2014; 20:6-8
34. Moraes CT, Bacman SR, Williams SL. Manipulating mitochondrial genomes in the clinic: playing by different rules. Trends Cell Biol 2014; 24:209-11
35. Smith PM, Lightowlers RN. Altering the balance between healthy and mutated mitochondrial DNA. J Inherit Metab Dis 2011; 34:309-13
36. Kyriakouli DS, Boesch P, Taylor RW, Lightowlers RN. Progress and prospects: gene therapy for mitochondrial DNA disease. Gene Ther 2008; 15:1017-23
37. Taylor RW, Chinnery PF, Turnbull DM, Lightowlers RN. Selective inhibition of mutant human mitochondrial DNA replication in vitro by peptide nucleic acids. Nat Genet 1997; 15:212-5
38. Comte C, Tonin Y, Heckel-Mager AM, Boucheham A, Smirnov A, Aure K, et al. Mitochondrial targeting of recombinant RNAs modulates the level of a heteroplasmic mutation in human mitochondrial DNA associated with Kearns Sayre Syndrome. Nucleic Acids Res 2013; 41:418-33
39. Tonin Y, Heckel AM, Dovydenko I, Meschaninova M, Comte C, Venyaminova A, et al. Characterization of chemically modified oligonucleotides targeting a pathogenic mutation in human mitochondrial DNA. Biochimie 2013
40. Tonin Y, Heckel AM, Dovydenko I, Meschaninova M, Comte C, Venyaminova A, et al. Characterization of chemically modified oligonucleotides targeting a pathogenic mutation in human mitochondrial DNA. Biochimie 2014; 100:192-9
41. Srivastava S, Moraes CT. Manipulating mitochondrial DNA heteroplasmy by a mitochondrially targeted restriction endonuclease. Hum Mol Genet 2001; 10:3093-9
42. Tanaka M, Borgeld HJ, Zhang J, Muramatsu S, Gong JS, Yoneda M, et al. Gene therapy for mitochondrial disease by delivering restriction endonuclease SmaI into mitochondria. J Biomed Sci 2002; 9:534-41
43. Bayona-Bafaluy MP, Blits B, Battersby BJ, Shoubridge EA, Moraes CT. Rapid directional shift of mitochondrial DNA heteroplasmy in animal tissues by a mitochondrially targeted restriction endonuclease. Proc Natl Acad Sci U S A 2005; 102:14392-7
44. Bacman SR, Williams SL, Garcia S, Moraes CT. Organ-specific shifts in mtDNA heteroplasmy following systemic delivery of a mitochondria-targeted restriction endonuclease. Gene Ther 2010; 17:713-20
45. Bacman SR, Williams SL, Duan D, Moraes CT. Manipulation of mtDNA heteroplasmy in all striated muscles of newborn mice by AAV9-mediated delivery of a mitochondria-targeted restriction endonuclease. Gene Ther 2012; 19:1101-6
46. Bacman SR, Williams SL, Hernandez D, Moraes CT. Modulating mtDNA heteroplasmy by mitochondria-targeted restriction endonucleases in a 'differential multiple cleavage-site' model. Gene Ther 2007; 14:1309-18
47. Minczuk M, Papworth MA, Miller JC, Murphy MP, Klug A. Development of a single-chain, quasi-dimeric zinc-finger nuclease for the selective degradation of mutated human mitochondrial DNA. Nucleic Acids Res 2008; 36:3926-38
48. Minczuk M, Kolasinska-Zwierz P, Murphy MP, Papworth MA. Construction and testing of engineered zinc-finger proteins for sequence-specific modification of mtDNA. Nat Protoc 2010; 5:342-56
49. Joung JK, Sander JD. TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol 2013; 14:49-55
50. Bacman SR, Williams SL, Pinto M, Peralta S, Moraes CT. Specific elimination of mutant mitochondrial genomes in patient-derived cells by mitoTALENs. Nat Med 2013; 19:1111-3
51. Gammage PA, Rorbach J, Vincent AI, Rebar EJ, Minczuk M. Mitochondrially targeted ZFNs for selective degradation of pathogenic mitochondrial genomes bearing large-scale deletions or point mutations. EMBO Mol Med 2014; 6:458-66
52. Moraes CT. A magic bullet to specifically eliminate mutated mitochondrial genomes from patients' cells. EMBO Mol Med 2014; 6:434-5
53. Nagley P, Farrell LB, Gearing DP, Nero D, Meltzer S, Devenish RJ. Assembly of functional proton-translocating ATPase complex in yeast mitochondria with cytoplasmically synthesized subunit 8, a polypeptide normally encoded within the organelle. Proc Natl Acad Sci U S A 1988; 85:2091-5
54. Perales-Clemente E, Fernandez-Silva P, Acin-Perez R, Perez-Martos A, Enriquez JA. Allotopic expression of mitochondrialencoded genes in mammals: achieved goal, undemonstrated mechanism or impossible task? Nucleic Acids Res 2011; 39:225-34
55. Manfredi G, Fu J, Ojaimi J, Sadlock JE, Kwong JQ, Guy J, et al. Rescue of a deficiency in ATP synthesis by transfer of MTATP6, a mitochondrial DNA-encoded gene, to the nucleus. Nat Genet 2002; 30:394-9
56. Ojaimi J, Pan J, Santra S, Snell WJ, Schon EA. An algal nucleusencoded subunit of mitochondrial ATP synthase rescues a defect in the analogous human mitochondrial-encoded subunit. Mol Biol Cell 2002; 13:3836-44
57. Bokori-Brown M, Holt IJ. Expression of algal nuclear ATP synthase subunit 6 in human cells results in protein targeting to mitochondria but no assembly into ATP synthase. Rejuvenation Res 2006; 9:455-69
58. Guy J, Qi X, Pallotti F, Schon EA, Manfredi G, Carelli V, et al. Rescue of a mitochondrial deficiency causing Leber Hereditary Optic Neuropathy. Ann Neurol 2002; 52:534-42
59. Oca-Cossio J, Kenyon L, Hao H, Moraes CT. Limitations of allotopic expression of mitochondrial genes in mammalian cells. Genetics 2003; 165:707-20
60. Bonnet C, Kaltimbacher V, Ellouze S, Augustin S, Benit P, Forster V, et al. Allotopic mRNA localization to the mitochondrial surface rescues respiratory chain defects in fibroblasts harboring mitochondrial DNA mutations affecting complex I or v subunits. Rejuvenation Res 2007; 10:127-44
61. Bonnet C, Augustin S, Ellouze S, Benit P, Bouaita A, Rustin P, et al. The optimized allotopic expression of ND1 or ND4 genes restores respiratory chain complex I activity in fibroblasts harboring mutations in these genes. Biochim Biophys Acta 2008; 1783:1707-17
62. Ellouze S, Augustin S, Bouaita A, Bonnet C, Simonutti M, Forster V, et al. Optimized allotopic expression of the human mitochondrial ND4 prevents blindness in a rat model of mitochondrial dysfunction. Am J Hum Genet 2008; 83:373-87
63. Lam BL, Feuer WJ, Abukhalil F, Porciatti V, Hauswirth WW, Guy J. Leber hereditary optic neuropathy gene therapy clinical trial recruitment: year 1. Arch Ophthalmol 2010; 128:1129-35
64. Lam BL, Feuer WJ, Schiffman JC, Porciatti V, Vandenbroucke R, Rosa PR, et al. Trial end points and natural history in patients with G11778A Leber hereditary optic neuropathy: preparation for gene therapy clinical trial. JAMA Ophthalmol 2014; 132:428-36
65. Koilkonda RD, Yu H, Chou TH, Feuer WJ, Ruggeri M, Porciatti V, et al. Safety and effects of the vector for the Leber hereditary optic neuropathy gene therapy clinical trial. JAMA Ophthalmol 2014; 132:409-20
66. Kolesnikova OA, Entelis NS, Jacquin-Becker C, Goltzene F, Chrzanowska-Lightowlers ZM, Lightowlers RN, et al. Nuclear DNA-encoded tRNAs targeted into mitochondria can rescue a mitochondrial DNA mutation associated with the MERRF syndrome in cultured human cells. Hum Mol Genet 2004; 13:2519-34
67. Rubio MA, Rinehart JJ, Krett B, Duvezin-Caubet S, Reichert AS, Soll D, et al. Mammalian mitochondria have the innate ability to import tRNAs by a mechanism distinct from protein import. Proc Natl Acad Sci U S A 2008; 105:9186-91
68. Wang G, Shimada E, Zhang J, Hong JS, Smith GM, Teitell MA, et al. Correcting human mitochondrial mutations with targeted RNA import. Proc Natl Acad Sci U S A 2012; 109:4840-5
69. Hornig-Do HT, Montanari A, Rozanska A, Tuppen HA, Almalki AA, Abg-Kamaludin DP, et al. Human mitochondrial leucyl tRNA synthetase can suppress non cognate pathogenic mt-tRNA mutations. EMBO Mol Med 2014; 6:183-93
70. Ling J, Roy H, Qin D, Rubio MA, Alfonzo JD, Fredrick K, et al. Pathogenic mechanism of a human mitochondrial tRNAPhe mutation associated with myoclonic epilepsy with ragged red fibers syndrome. Proc Natl Acad Sci U S A 2007; 104:15299-304
71. Rorbach J, Yusoff AA, Tuppen H, Abg-Kamaludin DP, Chrzanowska-Lightowlers ZM, Taylor RW, et al. Overexpression of human mitochondrial valyl tRNA synthetase can partially restore levels of cognate mt-tRNAVal carrying the pathogenic C25U mutation. Nucleic Acids Res 2008; 36:3065-74
72. Park H, Davidson E, King MP. Overexpressed mitochondrial leucyl-tRNA synthetase suppresses the A3243G mutation in the mitochondrial tRNA(Leu(UUR)) gene. RNA 2008; 14:2407-16
73. Li R, Guan MX. Human mitochondrial leucyl-tRNA synthetase corrects mitochondrial dysfunctions due to the tRNALeu(UUR) A3243G mutation, associated with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like symptoms and diabetes. Mol Cell Biol 2010; 30:2147-54
74. Karicheva OZ, Kolesnikova OA, Schirtz T, Vysokikh MY, Mager-Heckel AM, Lombes A, et al. Correction of the consequences of mitochondrial 3243A>G mutation in the MT-TL1 gene causing the MELAS syndrome by tRNA import into mitochondria. Nucleic Acids Res 2011; 39:8173-86
75. Perli E, Giordano C, Pisano A, Montanari A, Campese AF, Reyes A, et al. The isolated carboxy-terminal domain of human mitochondrial leucyl-tRNA synthetase rescues the pathological phenotype of mitochondrial tRNA mutations in human cells. EMBO Mol Med 2014; 6:169-82
76. Tyynismaa H, Schon EA. Mixing and matching mitochondrial aminoacyl synthetases and their tRNAs: a new way to treat respiratory chain disorders? EMBO Mol Med 2014; 6:155-7
77. Hakkaart GA, Dassa EP, Jacobs HT, Rustin P. Allotopic expression of a mitochondrial alternative oxidase confers cyanide resistance to human cell respiration. EMBO Rep 2006; 7:341-5
78. Dassa EP, Dufour E, Goncalves S, Jacobs HT, Rustin P. The alternative oxidase, a tool for compensating cytochrome c oxidase deficiency in human cells. Physiol Plant 2009; 137:427-34
79. El-Khoury R, Dufour E, Rak M, Ramanantsoa N, Grandchamp N, Csaba Z, et al. Alternative oxidase expression in the mouse enables bypassing cytochrome c oxidase blockade and limits mitochondrial ROS overproduction. PLoS Genet 2013; 9:e1003182
80. Bai Y, Hajek P, Chomyn A, Chan E, Seo BB, Matsuno-Yagi A, et al. Lack of complex I activity in human cells carrying a mutation in MtDNA-encoded ND4 subunit is corrected by the Saccharomyces cerevisiae NADH-quinone oxidoreductase (NDI1) gene. J Biol Chem 2001; 276:38808-13
81. Seo BB, Nakamaru-Ogiso E, Flotte TR, Matsuno-Yagi A, Yagi T. In vivo complementation of complex I by the yeast Ndi1 enzyme. Possible application for treatment of Parkinson disease. J Biol Chem 2006; 281:14250-5
82. Marella M, Seo BB, Nakamaru-Ogiso E, Greenamyre JT, Matsuno-Yagi A, Yagi T. Protection by the NDI1 gene against neurodegeneration in a rotenone rat model of Parkinson's disease. PLoS One 2008; 3:e1433
83. Barber-Singh J, Seo BB, Nakamaru-Ogiso E, Lau YS, Matsuno-Yagi A, Yagi T. Neuroprotective effect of long-term NDI1 gene expression in a chronic mouse model of Parkinson disorder. Rejuvenation Res 2009; 12:259-67
84. Marella M, Seo BB, Thomas BB, Matsuno-Yagi A, Yagi T. Successful amelioration of mitochondrial optic neuropathy using the yeast NDI1 gene in a rat animal model. PLoS One 2010; 5:e11472
85. Chadderton N, Palfi A, Millington-Ward S, Gobbo O, Overlack N, Carrigan M, et al. Intravitreal delivery of AAV-NDI1 provides functional benefit in a murine model of Leber hereditary optic neuropathy. Eur J Hum Genet 2013; 21:62-8
86. Vilain S, Esposito G, Haddad D, Schaap O, Dobreva MP, Vos M, et al. The yeast complex I equivalent NADH dehydrogenase rescues pink1 mutants. PLoS Genet 2012; 8:e1002456
87. Smith RA, Hartley RC, Cocheme HM, Murphy MP. Mitochondrial pharmacology. Trends Pharmacol Sci 2012; 33:341-52
88. Smith RA, Murphy MP. Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Ann N Y Acad Sci 2010; 1201:96-103
89. Miquel E, Cassina A, Martinez-Palma L, Souza JM, Bolatto C, Rodriguez-Bottero S, et al. Neuroprotective effects of the mitochondria-targeted antioxidant MitoQ in a model of inherited amyotrophic lateral sclerosis. Free Radic Biol Med 2014; 70:204-13
90. Snow BJ, Rolfe FL, Lockhart MM, Frampton CM, O'Sullivan JD, Fung V, et al. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a diseasemodifying therapy in Parkinson's disease. Mov Disord 2010; 25: 1670-4
91. Birk AV, Chao WM, Bracken C, Warren JD, Szeto HH. Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis. Br J Pharmacol 2014; 171:2017-28
92. Szeto HH, Schiller PW. Novel therapies targeting inner mitochondrial membrane-from discovery to clinical development. Pharm Res 2011; 28:2669-79
93. Petri S, Kiaei M, Damiano M, Hiller A, Wille E, Manfredi G, et al. Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. J Neurochem 2006; 98:1141-8
94. Yang L, Zhao K, Calingasan NY, Luo G, Szeto HH, Beal MF. Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Antioxid Redox Signal 2009; 11:2095-104
95. Manczak M, Mao P, Calkins MJ, Cornea A, Reddy AP, Murphy MP, et al. Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons. J Alzheimers Dis 2010; 20 Suppl 2:S609-31
96. Siegel MP, Kruse SE, Percival JM, Goh J, White CC, Hopkins HC, et al. Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell 2013; 12:763-71
97. Fink MP, Macias CA, Xiao J, Tyurina YY, Jiang J, Belikova N, et al. Hemigramicidin-TEMPO conjugates: novel mitochondriatargeted anti-oxidants. Biochem Pharmacol 2007; 74:801-9
98. Xun Z, Rivera-Sanchez S, Ayala-Pena S, Lim J, Budworth H, Skoda EM, et al. Targeting of XJB-5-131 to mitochondria suppresses oxidative DNA damage and motor decline in a mouse model of Huntington's disease. Cell Rep 2012; 2:1137-42
99. Battigelli A, Russier J, Venturelli E, Fabbro C, Petronilli V, Bernardi P, et al. Peptide-based carbon nanotubes for mitochondrial targeting. Nanoscale 2013; 5:9110-7
100. Wenz T, Diaz F, Spiegelman BM, Moraes CT. Activation of the PPAR/PGC-1alpha pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype. Cell Metab 2008; 8:249-56
101. Yatsuga S, Suomalainen A. Effect of bezafibrate treatment on lateonset mitochondrial myopathy in mice. Hum Mol Genet 2012; 21:526-35
102. Viscomi C, Bottani E, Civiletto G, Cerutti R, Moggio M, Fagiolari G, et al. In vivo correction of COX deficiency by activation of the AMPK/PGC-1alpha axis. Cell Metab 2011; 14:80-90
103. Johri A, Calingasan NY, Hennessey TM, Sharma A, Yang L, Wille E, et al. Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease. Hum Mol Genet 2012; 21:1124-37
104. Dumont M, Stack C, Elipenahli C, Jainuddin S, Gerges M, Starkova N, et al. Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice. Hum Mol Genet 2012; 21:5091-105
105. Noe N, Dillon L, Lellek V, Diaz F, Hida A, Moraes CT, et al. Bezafibrate improves mitochondrial function in the CNS of a mouse model of mitochondrial encephalopathy. Mitochondrion 2013; 13:417-26
106. Miller BW, Willett KC, Desilets AR. Rosiglitazone and pioglitazone for the treatment of Alzheimer's disease. Ann Pharmacother 2011; 45:1416-24
107. Carta AR. PPAR-gamma: therapeutic prospects in Parkinson's disease. Curr Drug Targets 2013; 14:743-51
108. Wilkins HM, Harris JL, Carl SM, E L, Lu J, Eva Selfridge J, et al. Oxaloacetate activates brain mitochondrial biogenesis, enhances the insulin pathway, reduces inflammation and stimulates neurogenesis. Hum Mol Genet 2014
109. Guedes-Dias P, Oliveira JM. Lysine deacetylases and mitochondrial dynamics in neurodegeneration. Biochim Biophys Acta 2013; 1832:1345-59
110. Brenmoehl J, Hoeflich A. Dual control of mitochondrial biogenesis by sirtuin 1 and sirtuin 3. Mitochondrion 2013
111. Gong B, Pan Y, Vempati P, Zhao W, Knable L, Ho L, et al. Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-gamma coactivator 1alpha regulated beta-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models. Neurobiol Aging 2013; 34:1581-8
112. Pirinen E, Canto C, Jo YS, Morato L, Zhang H, Menzies KJ, et al. Pharmacological Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle. Cell Metab 2014; 19:1034-41
113. Khan NA, Auranen M, Paetau I, Pirinen E, Euro L, Forsstrom S, et al. Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3. EMBO Mol Med 2014; 6:721-31
114. Cerutti R, Pirinen E, Lamperti C, Marchet S, Sauve AA, Li W, et al. NAD(+)-dependent activation of Sirt1 corrects the phenotype in a mouse model of mitochondrial disease. Cell Metab 2014; 19:1042-9
115. Lightowlers RN, Chrzanowska-Lightowlers ZM. Salvaging hope: Is increasing NAD(+) a key to treating mitochondrial myopathy? EMBO Mol Med 2014; 6:705-7
116. Lira VA, Benton CR, Yan Z, Bonen A. PGC-1alpha regulation by exercise training and its influences on muscle function and insulin sensitivity. Am J Physiol Endocrinol Metab 2010; 299:E145-61
117. Steiner JL, Murphy EA, McClellan JL, Carmichael MD, Davis JM. Exercise training increases mitochondrial biogenesis in the brain. J Appl Physiol (1985) 2011; 111:1066-71
118. Zhang Q, Wu Y, Zhang P, Sha H, Jia J, Hu Y, et al. Exercise induces mitochondrial biogenesis after brain ischemia in rats. Neuroscience 2012; 205:10-7
119. Wang X, Su B, Lee HG, Li X, Perry G, Smith MA, et al. Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J Neurosci 2009; 29:9090-103
120. Chen H, Chan DC. Mitochondrial dynamics-fusion, fission, movement, and mitophagy-in neurodegenerative diseases. Hum Mol Genet 2009; 18:R169-76
121. Wang D, Wang J, Bonamy GM, Meeusen S, Brusch RG, Turk C, et al. A small molecule promotes mitochondrial fusion in mammalian cells. Angew Chem Int Ed Engl 2012; 51:9302-5
122. Lackner LL, Nunnari J. Small molecule inhibitors of mitochondrial division: tools that translate basic biological research into medicine. Chem Biol 2010; 17:578-83
123. Cui M, Tang X, Christian WV, Yoon Y, Tieu K. Perturbations in mitochondrial dynamics induced by human mutant PINK1 can be rescued by the mitochondrial division inhibitor mdivi-1. J Biol Chem 2010; 285:11740-52
124. Xie N, Wang C, Lian Y, Zhang H, Wu C, Zhang Q. A selective inhibitor of Drp1, mdivi-1, protects against cell death of hippocampal neurons in pilocarpine-induced seizures in rats. Neurosci Lett 2013; 545:64-8
125. Park SW, Kim KY, Lindsey JD, Dai Y, Heo H, Nguyen DH, et al. A selective inhibitor of drp1, mdivi-1, increases retinal ganglion cell survival in acute ischemic mouse retina. Invest Ophthalmol Vis Sci 2011; 52:2837-43
126. Zhang N, Wang S, Li Y, Che L, Zhao Q. A selective inhibitor of Drp1, mdivi-1, acts against cerebral ischemia/reperfusion injury via an anti-apoptotic pathway in rats. Neurosci Lett 2013; 535:104-9
127. Qi X, Qvit N, Su YC, Mochly-Rosen D. A novel Drp1 inhibitor diminishes aberrant mitochondrial fission and neurotoxicity. J Cell Sci 2013; 126:789-802
128. Guo X, Disatnik MH, Monbureau M, Shamloo M, Mochly-Rosen D, Qi X. Inhibition of mitochondrial fragmentation diminishes Huntington's disease-associated neurodegeneration. J Clin Invest 2013; 123:5371-88
129. Hempen B, Brion JP. Reduction of acetylated alpha-tubulin immunoreactivity in neurofibrillary tangle-bearing neurons in Alzheimer's disease. J Neuropathol Exp Neurol 1996; 55:964-72
130. Dompierre JP, Godin JD, Charrin BC, Cordelieres FP, King SJ, Humbert S, et al. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J Neurosci 2007; 27:3571-83
131. Kim C, Choi H, Jung ES, Lee W, Oh S, Jeon NL, et al. HDAC6 inhibitor blocks amyloid beta-induced impairment of mitochondrial transport in hippocampal neurons. PLoS One 2012; 7:e42983
132. Govindarajan N, Rao P, Burkhardt S, Sananbenesi F, Schluter OM, Bradke F, et al. Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease. EMBO Mol Med 2013; 5:52-63
133. d'Ydewalle C, Krishnan J, Chiheb DM, Van Damme P, Irobi J, Kozikowski AP, et al. HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease. Nat Med 2011; 17:968-74
134. Kim JY, Shen S, Dietz K, He Y, Howell O, Reynolds R, et al. HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage. Nat Neurosci 2010; 13:180-9
135. Oliveira JM, Chen S, Almeida S, Riley R, Goncalves J, Oliveira CR, et al. Mitochondrial-dependent Ca2+ handling in Huntington's disease striatal cells: effect of histone deacetylase inhibitors. J Neurosci 2006; 26:11174-86
136. Batlevi Y, La Spada AR. Mitochondrial autophagy in neural function, neurodegenerative disease, neuron cell death, and aging. Neurobiol Dis 2011; 43:46-51
137. Kanki T, Klionsky DJ. Mitophagy in yeast occurs through a selective mechanism. J Biol Chem 2008; 283:32386-93
138. Ashrafi G, Schwarz TL. The pathways of mitophagy for quality control and clearance of mitochondria. Cell Death Differ 2013; 20:31-42
139. Davis CH, Kim KY, Bushong EA, Mills EA, Boassa D, Shih T, et al. Transcellular degradation of axonal mitochondria. Proc Natl Acad Sci U S A 2014; 111:9633-8
140. Van Laar VS, Arnold B, Cassady SJ, Chu CT, Burton EA, Berman SB. Bioenergetics of neurons inhibit the translocation response of Parkin following rapid mitochondrial depolarization. Hum Mol Genet 2011; 20:927-40
141. Grenier K, McLelland GL, Fon EA. Parkin-and PINK1-Dependent Mitophagy in Neurons: Will the Real Pathway Please Stand Up? Front Neurol 2013; 4:100
142. Wang X, Winter D, Ashrafi G, Schlehe J, Wong YL, Selkoe D, et al. PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. Cell 2011; 147:893-906
143. Cai Q, Zakaria HM, Simone A, Sheng ZH. Spatial parkin translocation and degradation of damaged mitochondria via mitophagy in live cortical neurons. Curr Biol 2012; 22:545-52
144. Bingol B, Tea JS, Phu L, Reichelt M, Bakalarski CE, Song Q, et al. The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy. Nature 2014; 510:370-5
145. Suen DF, Narendra DP, Tanaka A, Manfredi G, Youle RJ. Parkin overexpression selects against a deleterious mtDNA mutation in heteroplasmic cybrid cells. Proc Natl Acad Sci U S A 2010; 107:11835-40.